This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Last November, I initiated coverage on Vertex Pharmaceutical Inc. (NASDAQ: VRTX ) suggesting the stock as a strong buy around $461/share. This was due to the commercialization potential of three drugs, namely CASGEVY, JOURNAVX (suzetrigine) and ALYFTREK (vanzacaftor triple). In mid-December Vertex saw a volatile period punctuatedBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).- ...

Key TakeawaysVertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration.The drugmaker said the twice-daily pill, Journavx, is the first such treatment to hit the market in 20 years.Vertex set the U.S. wholesale price of Journavx at $15.50 per 50mg pill. Shares of Vertex Pharmaceuticals (VRTX) surged Friday, a day after the drugmaker reported federal regulators have approved its non-opioid painkiller, the first such drug to head to market in two decades. The company ...

The Food and Drug Administration on Thursday approved Vertex Pharmaceuticals' non-opioid painkiller pill, a new alternative for pain relief that comes without the risk of addiction. Vertex is now the first drugmaker in decades to gain U.S. approval for a new type of pain medicine. It's a milestone after a long history of mostly unsuccessful efforts to develop painkillers without the destructive dependency of cheap and widely available opioids, which have caused a horrific epidemic of abuse and overdose in t ...

The 2024 End-of-Year Report showcases significant changes in the tax landscape, indicating additional complexity in 2025KING OF PRUSSIA, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, today released the findings of their 2024 U.S. state and local End-of-Year Rates and Rules Report. It highlights notable growth in district-level tax activity, including an increase in new district taxes and rate changes, as local gov ...

Vertex (VERX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing ...

The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds. Rising interest rates, challenges in the U.S. healthcare system, and the inherent risks of drug development have contributed to the sector's underperformance relative to the broader markets during this period.However, some healthcare companies have bucked this downward trend in the post-pandemic era. Notably, Vertex Pharmaceuticals (VRTX -0.03%), which focuses on developing treatmen ...

The stock of Vertex Pharmaceuticals Incorporated (VRTX) has declined almost 13% in the past six months.A key reason for the stock price decline was unimpressive data from a phase II study on its key pipeline candidate, suzetrigine, for painful lumbosacral radiculopathy (LSR), a form of peripheral neuropathic pain, which showed largely undifferentiated pain reduction from placebo. Despite the unimpressive data in phase II, management decided to forge ahead to a phase III study in this indication, which is co ...

Have you been paying attention to shares of Vertex (VERX) ? Shares have been on the move with the stock up 5.8% over the past month. The stock hit a new 52-week high of $58.22 in the previous session. Vertex has gained 6.2% since the start of the year compared to the 37.2% move for the Zacks Computer and Technology sector and the 41.7% return for the Zacks Internet - Software industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't missed our ...

KING OF PRUSSIA, Pa., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced that it will release fourth quarter 2024 financial results before the market opens on Thursday, February 27, 2025. A conference call to discuss the results will be held at 8:30 a.m. Eastern Time that same day. Those wishing to participate may do so by dialing 1-412-317-6026 approximately ten minutes prior to start time. A listen-only webcast of t ...